POMPANO BEACH, Fla. — August 21, 2025 — Leads & Copy — BioStem Technologies, Inc. (OTC: BSEM) announced that Jason Matuszewski, Chairman and CEO, purchased 15,500 shares of the company’s common stock on August 19, 2025, for approximately $100,000.
The purchases were made through two transactions: 2,500 shares at an average of $6.28 and 13,000 shares at $6.51. Matuszewski now owns 1,145,362 shares.
BioStem Technologies focuses on developing, manufacturing, and commercializing placental-derived products for wound care, leveraging its BioREtain® processing method. Its brands include AmnioWrap2™, VENDAJE®, VENDAJE AC®, and VENDAJE OPTIC®.
The company’s products are processed at its FDA-registered and AATB-accredited site in Pompano Beach, Florida.
Contacts:
Adam Holdsworth, BioStem Director of Investor Relations, adam@biostemtech.com, 917-497-9287
Philip Trip Taylor, Principal, Gilmartin Group, philip@gilmartinir.com, 415-937-5406
Source: BioStem Technologies, Inc.
